Company intelligence / Profile preview
Artiva Biotherapeutics, Inc.
San Diego, California, United Statesartivabio.com ↗
- Ownership
- Public · ARTV
- Development stage
- Phase 1
01
Overview
AlloNK (AB-101) is being evaluated in clinical trials for autoimmune diseases and cancer. In NHL trials, it has demonstrated deep B-cell depletion and durable responses. The first patient with lupus nephritis was dosed in a Phase 1 trial in 2024. Initial data from the autoimmune program is expected in H1 2025, and updated NHL trial data will be presented at a medical conference in 2025[3][9].
- Therapeutic areas
- OncologyImmunology
- Modalities
- Natural killer (NK) cell-based therapiesCAR-NK cell therapies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Affimed N.V. (for AlloNK + AFM13 combination therapy)Lupus Therapeutics (for AlloNK development through Lupus Clinical Investigators Network sites)
04
Financials
- Market cap
- $201.9M
- Total revenue
- $0
- Enterprise value
- $-137.6M
Beyond the preview
Go deeper on Artiva Biotherapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Artiva Biotherapeutics, Inc..